The following is a summary of “Nirmatrelvir–ritonavir versus placebo–ritonavir in individuals with long COVID in the USA (PAX LC): a double-blind, randomised, placebo-controlled, phase 2, decentralised trial,” published in the April 2025 issue of Lancet Infectious Diseases by Sawano et al. Researchers conducted a retrospective study to evaluate the efficacy, safety, and tolerability of nirmatrelvir–ritonavir […]
The post Long COVID Outcomes With Nirmatrelvir Ritonavir Therapy first appeared on Physician’s Weekly.
